-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Student Activism Shifts Underground After University Crackdown on Gaza Encampments
-
Kiss of Life Teases First Winter Single 'Greedy'
-
Surge in Early Social Security Claims Linked to Agency Turmoil
-
Eight-Year-Old Georgia Wins Penrith Valley Public Speaking Competition
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Who Does the Best Rhinoplasty in Sarasota?
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
Dateline appoints Tony Ferguson as Acting Chairman
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
West Midlands Shoppers Urged to Guard Against Black Friday Scams
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Surfshark Adds Real-Time Call Protection to iOS App in Version 5.3.0
-
Samsung Galaxy Buds Active Leak Reveals ANC, Ear-Hook Design and One UI 9.5 Integration
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
US approves first blood test for Alzheimer's
The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the devastating neurological disease.
The test, developed by Fujirebio Diagnostics, measures the ratio of two proteins in the blood. The rato is correlated with amyloid plaques in the brain -- a hallmark of Alzheimer's that, until now, has been detected only through brain scans or spinal fluid analysis.
"Alzheimer's disease impacts too many people -- more than breast cancer and prostate cancer combined," said Food and Drug Administration Commissioner Marty Makary.
"Knowing that 10 percent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients."
There are currently two FDA approved treatments for Alzheimer's: lecanemab and donanemab, which target amyloid plaque and have been shown to modestly slow cognitive decline, though they do not cure the disease.
Advocates for the intravenous antibody therapies, including many neurologists, say they can offer patients a few additional months of independence -- and are likely to be more effective if started earlier in the disease's course.
In clinical studies, the blood test produced results largely in line with positron emission tomography (PET) brain scans and spinal fluid analysis.
"Today's clearance is an important step for Alzheimer's diagnosis, making it easier and potentially more accessible for US patients earlier in the disease," said Michelle Tarver of the FDA's Center for Devices and Radiological Health.
The test is authorized for use in clinical settings for patients showing signs of cognitive decline, and results must be interpreted alongside other clinical information.
Alzheimer's is the most common form of dementia. It worsens over time, gradually robbing people of their memories and independence.
F.Dubois--AMWN